Celgene
Also known as: Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation | Celgene | CELGENE | Celgene Austria | Celgene/BMS | Celgene Cellular Therapeutics, a division of Celgene Corporation | CELGENE CORP | Celgene Corporation | Celgene Inc | Celgene International II SARL | Celgene International II S.á.r.l. | CELGENE INTL | Celgene KK | Celgene K.K | Celgene K.K. | Celgene Korea | Celgene Medical Director | Celgene Pharmaceutical (Shanghai) Co. Ltd. | Celgene s.r.l. | Celgene Therapeutic Area Head | Clinical Research Manager, Celgene Korea | Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation | Medical Affairs Myeloid Diseases Lead for Celgene Europe | Study physician for Celgene
Highest phase reached
Phase 4
First clinical trial
Aug 1, 1998First marketed drug
Jul 16, 1998First NDA
Jul 16, 1998Last known activity
Dec 16, 2025
Timeline
1980s
- Jan 1, 1986
Celgene— Founded
2000s
- Mar 7, 2000
Signal Pharmaceuticals— Acquired
- Jan 1, 2002
Anthrogenesis— Acquired
- Jan 1, 2007
Pharmion— Acquired
- Jan 15, 2009
Gloucester Pharmaceuticals— Acquired
- Nov 5, 2009
romidepsin— NDA Secondary Org
2010s
- Jan 1, 2010
Abraxis— Acquired
- Jan 29, 2012
Avila Therapeutics— Acquired
- Jan 1, 2015
Quanticel Pharmaceuticals— Acquired
- Jan 1, 2015
Receptos— Acquired
- Sep 30, 2016
EngMab AG— Acquired
- Dec 2, 2016
Acetylon Pharmaceuticals Incorporated— Acquired
- Jan 1, 2017
Delinia, Inc.— Acquired
- Feb 14, 2017
VentiRx Pharmaceuticals Inc.— Acquired
- Jan 8, 2018
Impact Biomedicines— Acquired
- Jan 22, 2018
Juno Therapeutics, Inc.— Acquired
- Jan 3, 2019
Bristol-Myers Squibb— Acquired By
- Aug 16, 2019
fedratinib— NDA Organization
- Nov 8, 2019
luspatercept— Marketing Organization
Drugs by trial phase (288 distinct, 1074 trials)
Phase 4 (3 own, 2 via acquisition)
Phase 3 (61 own, 10 via acquisition)
Phase 2 (104 own, 11 via acquisition)
Phase 1 (86 own, 10 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acne Conglobata
- Acne Vulgaris
- Acquired Immunodeficiency Syndrome
- Acute Disease
- Adenocarcinoma
- Adenocarcinoma, Follicular
- Adenocarcinoma of Lung
- Agammaglobulinemia
- Aggression
- Alopecia
- Alopecia Areata
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Anemia
- Anemia, Refractory, with Excess of Blasts
- Anemia, Sickle Cell
- Angina Pectoris
- Arachnoiditis
- Arthritis
- Arthritis, Gouty
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Astrocytoma
- Autoimmune Diseases
- Behcet Syndrome
- beta-Thalassemia
- Biliary Tract Neoplasms
- Blast Crisis
- Blood Protein Disorders
- Bone Marrow Diseases
- Brain Diseases
- Brain Ischemia
- Brain Neoplasms
- Breast Neoplasms
- Breast Neoplasms, Male
- Burkitt Lymphoma
- Cachexia
- Cancer Pain
- Carcinoma
- Carcinoma, Adenoid Cystic
- Carcinoma, Adenosquamous
- Carcinoma, Ductal
- Carcinoma, Ductal, Breast
- Carcinoma, Hepatocellular
- Carcinoma, Large Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Pancreatic Ductal
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cardiovascular Diseases
- Central Nervous System Neoplasms
- Cholangiocarcinoma
- Cholangitis
- Cholangitis, Sclerosing
- Cholestasis
- Chondrosarcoma
- Chromosome Aberrations
- Chromosome Disorders
- Chronic Disease
- Colitis
- Colitis, Ulcerative
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Complex Regional Pain Syndromes
- Congenital Abnormalities
- Coronary Artery Disease
- Coronary Restenosis
- Crohn Disease
- Dermatitis
- Dermatitis, Allergic Contact
- Dermatitis, Atopic
- Dermatitis, Contact
- Dermatofibrosarcoma
- Diabetic Foot
- Diabetic Nephropathies
- Diarrhea
- Digestive System Diseases
- Digestive System Neoplasms
- Disease
- Eczema
- Endocrine Gland Neoplasms
- Endocrine System Diseases
- Endometriosis
- Enteropathy-Associated T-Cell Lymphoma
- Eosinophilic Esophagitis
- Erdheim-Chester Disease
- Esophageal Neoplasms
- Esophagitis
- Fallopian Tube Neoplasms
- Fatigue
- Fatty Liver
- Fibrosarcoma
- Fibrosis
- Foot Ulcer
- Frailty
- Gallbladder Neoplasms
Marketed drugs (10)
Subsidiaries (14 direct, 20 total across the full acquisition tree)
- Abraxis
- Acetylon Pharmaceuticals Incorporated
- Anthrogenesis
- Avila Therapeutics
- Delinia, Inc.
- EngMab AG
- Gloucester Pharmaceuticals
- Impact Biomedicines
- Juno Therapeutics, Inc.
- Pharmion
- Quanticel Pharmaceuticals
- Receptos
- Signal Pharmaceuticals
- VentiRx Pharmaceuticals Inc.
- AbVitro L2
- American Bioscience L2
- American Pharmaceutical Partners L2
- Redox Therapies L2
- Stage Cell Therapeutics L2
- X-Body L2
Recent trials (50)
- NCT03723083Lead sponsorN/A—
- NCT03724227Lead sponsorN/A—
- NCT03740516Lead sponsorN/A—
- NCT04644107Lead sponsorN/A—
- NCT03723148Lead sponsorN/A—
- NCT03723148CollaboratorN/A—
- NCT04771078Lead sponsorN/A—
- NCT03723057Lead sponsorN/A—
- NCT03723096Lead sponsorN/A—
- NCT03723135Lead sponsorN/A—
- NCT07032714CollaboratorPhase 1Dec 16, 2025
- NCT07242781Lead sponsorPhase 1Dec 8, 2025
- NCT06988488Lead sponsorPhase 1/Phase 2Oct 7, 2025
- NCT06808984Lead sponsorPhase 2Apr 15, 2025
- NCT06782490Lead sponsorPhase 2Mar 14, 2025
Details
- Founded
- Summit, NJ, US Jan 1, 1986
- First NDA
- Jul 16, 1998
- Last known activity
- Dec 16, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval